NASDAQ:RTTR - Ritter Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.31 +0.01 (+0.43 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$2.30
Today's Range$2.25 - $2.33
52-Week Range$1.80 - $6.50
Volume21,100 shs
Average Volume101,448 shs
Market Capitalization$12.25 million
P/E Ratio-0.46
Dividend YieldN/A
Ritter Pharmaceuticals logoRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio23.86
Quick Ratio23.86


Trailing P/E Ratio-0.46
Forward P/E Ratio-0.80
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.03 per share
Price / Book0.76


EPS (Most Recent Fiscal Year)($5.00)
Net Income$-7,860,000.00
Net MarginsN/A
Return on Equity-136.12%
Return on Assets-85.45%


Outstanding Shares5,020,000
Market Cap$12.25

The Truth About Cryptocurrencies

Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Ritter Pharmaceuticals's stock reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) released its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.01. View Ritter Pharmaceuticals' Earnings History.

What price target have analysts set for RTTR?

4 brokerages have issued 12 month price objectives for Ritter Pharmaceuticals' shares. Their predictions range from $15.00 to $20.00. On average, they anticipate Ritter Pharmaceuticals' stock price to reach $16.6667 in the next year. This suggests a possible upside of 621.5% from the stock's current price. View Analyst Ratings for Ritter Pharmaceuticals.

What is the consensus analysts' recommendation for Ritter Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ritter Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Ritter Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ritter Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We note that the company recorded a net loss per share of $0.41, roughly in-line with our projection of a net loss per share of $0.42. Investors should note that the prior quarterly numbers reflect pre-split calculations. Ritter conducted a 1- for-10 reverse stock split in March 2018. In the wake of these results and in anticipation of the presentation of two posters on aspects of the Phase 2b data from the previously-concluded trial of RP-628—both clinical impact and background on the patient evaluation tool used in the study—at the Digestive Disease Week (DDW) medical conference in Washington, DC at the beginning of June, we reiterate our Buy rating and 12-month price target of $15.00 per share on RTTR. RP-G28 slated to enter pivotal development near term." (5/29/2018)
  • 2. According to Zacks Investment Research, "Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. " (5/8/2018)

Who are some of Ritter Pharmaceuticals' key competitors?

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:
  • Mr. Ira E. Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 69)
  • Mr. Michael D. Step, CEO & Director (Age 58)
  • Mr. Andrew J. Ritter, Co-Founder, Pres, Corp. Sec. & Director (Age 35)
  • Mr. Jeffrey Benjamin, Principal Financial & Accounting Officer (Age 53)
  • Mr. John W. Beck CPA, Chief Financial Officer (Age 58)

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an initial public offering (IPO) on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.

Has Ritter Pharmaceuticals been receiving favorable news coverage?

Media stories about RTTR stock have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a news sentiment score of 0.02 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Ritter Pharmaceuticals?

Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $2.31.

How big of a company is Ritter Pharmaceuticals?

Ritter Pharmaceuticals has a market capitalization of $12.25 million. The biotechnology company earns $-7,860,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Ritter Pharmaceuticals employs 9 workers across the globe.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]

MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  334
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.